The impact of lactotripeptides on blood pressure response in stage 1 and stage 2 hypertensives
| Autor: | Sheldon S. Hendler, Joel M. Neutel, Mako Nonaka, F. Wilford Germino |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Ambulatory blood pressure Endocrinology Diabetes and Metabolism Population Placebo Prehypertension Drug Administration Schedule chemistry.chemical_compound Double-Blind Method Internal medicine Internal Medicine medicine Humans Prospective Studies Prospective cohort study education Antihypertensive Agents Aged education.field_of_study Lactotripeptides Dose-Response Relationship Drug business.industry Blood Pressure Monitoring Ambulatory Middle Aged Original Papers Surgery Drug Combinations Blood pressure chemistry Ambulatory Hypertension Cardiology Female Cardiology and Cardiovascular Medicine business Oligopeptides |
| Zdroj: | J Clin Hypertens (Greenwich) |
| ISSN: | 1751-7176 |
| Popis: | J Clin Hypertens (Greenwich). 2010;12:153–159. (©)2010 Wiley Periodicals, Inc. Nearly 70 million Americans have hypertension, and approximately an equal number have prehypertension. The prevalence of both disorders increases with advancing age and obesity. Many at‐risk individuals do not have controlled blood pressure (BP). Lifestyle modification for most persons is the first step in a plan to control these conditions. Non–drug treatments offer an appeal to many patients with modest BP elevation. The authors recently evaluated BP response using 24‐hour ambulatory BP monitoring and office BP monitoring of lactotripeptides dosed twice daily in 91 previously treated and treatment‐naive patients with stage 1 and stage 2 hypertension. In this population, daytime systolic BP, the primary efficacy end point, significantly decreased (−3.6 mm Hg; P=.013), while placebo did not affect systolic BP (0 mm Hg; P=not significant). Treatment‐naive patients exhibited a more robust drop in their daytime systolic BP (−7.6 mm Hg; P=.005) compared with placebo (−3.6 mm Hg; P=not significant). Lactotripeptides may be an effective agent in the management of low‐risk and low‐grade hypertension and prehypertension. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|